Drug intelligence / Profile preview

Placebo + MK6349

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules

Overview

This is a combination of a placebo and MK6349, a small molecule drug developed by Merck for the treatment of Type 2 Diabetes Mellitus. The mechanism of action for MK6349 is unknown. The combination is likely used in clinical trials to compare the effects of MK6349 against a placebo.

Targets

Tau aggregates (Microtubule-associated protein tau (pathological form))

Beyond the preview

Go deeper on Placebo + MK6349.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Placebo + MK6349.

Explore the full profile